Editorial disclosure: This article is original educational commentary based on the cited literature. It summarizes and interprets published evidence rather than reproducing source text. Clinical decisions should be based on the full original publications, current guidelines, regulatory status, and individual patient factors.
Why continuous pharmacokinetic monitoring matters
Drug dosing in kidney disease is usually based on intermittent laboratory measurements. Serum creatinine and estimated GFR are useful, but they are indirect measures of drug clearance and can change more slowly than the underlying pharmacokinetic disturbance.
A 2026 Science Translational Medicine study tested a minimally invasive microneedle biosensor capable of monitoring drug-related pharmacokinetic signals in the interstitial fluid of rats. The investigators translated interstitial-fluid measurements into blood-equivalent pharmacokinetic parameters, and vancomycin measurements correlated with blood concentrations.
Promising, but preclinical
In rats with kidney injury, reduced drug clearance detected by the biosensor was concordant with reduced GFR, and the signal changed as kidney function recovered. The biosensor detected impaired drug clearance before the rise in blood creatinine in the experimental model.
Drugs with narrow therapeutic windows—including selected antimicrobials, immunosuppressants and oncology agents—could eventually benefit from more frequent monitoring. However, the evidence is from animal models. Human accuracy, calibration, safety and clinical outcome benefit remain to be demonstrated.
Key clinical takeaways
- Microneedle biosensors have shown preclinical potential for pharmacokinetic monitoring.
- The current evidence is in animals, not routine human care.
- Continuous drug-clearance monitoring could eventually transform therapeutic drug monitoring.
References
- Wang M. Wearable biosensor can detect impaired kidney drug clearance. Nat Rev Nephrol. 2026;22:384. DOI.
- Zhu J, et al. Resilient nanostructured bioanalytic microneedle longitudinally monitors preclinical renal and hepatic drug clearance and dysfunction. Sci Transl Med. 2026;18:eadr5493.